Voluntary Recall of four (4) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg
Jul 27, 2022
Public Communication Important Safety Information on APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg |
Date: 04/27/2022
Voluntary Recall of four (4) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg.
Apotex has initiated a voluntary Type I recall to the Pharmacy Level for four (4) lots of “APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard)”. This recall is being initiated due to three lots (RH9369, TE5062 & TH6119) in which the acceptable intake limit for N-nitrosodimethylamine (NDMA), as established by Health Canada, has been exceeded. Out of an abundance of caution, the company extends the recall to include one (1) additional one lot (TF4466). NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables. The details for the lots being recalled are listed below:
PRODUCT |
DIN |
UPC |
STRENGTH |
SIZE / FORMAT |
LOT |
EXP. DATE (mm/yyyy) |
---|---|---|---|---|---|---|
APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) |
02207621 |
771313080316 |
200 mg |
100 BTL |
RH9369 TF4466 |
08/2022 08/2024 |
02207656 |
771313080347 |
800 mg |
100 BTL |
TE5062 TH6119 |
06/2023 12/2023 |
APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) is indicated for the treatment of initial episodes of herpes genitalis, for the suppression of unusually frequent recurrences of herpes genitalis (6 or more episodes per year) and for acute treatment of herpes zoster (shingles).
To report a suspected adverse reaction associated with the use of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) patients may contact Apotex by calling 1-800-667-4708 or 416-401-7780 (follow prompts), by email at drug.safety@apotex.com or by fax at 1-866-429-9133 or 416-401-3819.
Patients may also report any suspected adverse reactions associated with the use of health products to Health Canada by calling toll free at 1-866-234-2345 or by visiting MedEffect Canada's Web page on Adverse Reaction Reporting https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html for information on how to report online, by mail or by fax.
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 1, 2025
Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, yesterday announced a grant through the Apotex Global Health Access Fund to the Foundation for Mother and Child Health ("FMCH") in Mumbai, India to support programs that promote maternal health and address child malnutrition.